{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:45:04Z","timestamp":1784256304494,"version":"3.55.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","surveyophthalmol.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.survophthal.2025.02.005","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T16:27:41Z","timestamp":1740846461000},"page":"633-644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacological agents for treatment of proliferative vitreoretinopathy: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"70","author":[{"given":"Sina","family":"Khosravi Mirzaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firouze","family":"Hatami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sare","family":"Safi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Khorrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Khosravi Shadmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohamadmehdi","family":"Moshtaghion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-2661","authenticated-orcid":false,"given":"Hamid","family":"Ahmadieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.survophthal.2025.02.005_bib1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.ophtha.2008.05.016","article-title":"Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial","volume":"115","author":"Ahmadieh","year":"2008","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2025.02.005_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.51329\/mehdiophthal1452","article-title":"Intravitreal methotrexate infusion for prophylaxis of proliferative vitreoretinopathy after pars plana vitrectomy for rhegmatogenous retinal detachment","volume":"11","author":"Aziz","year":"2022","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.02.005_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"netmeta: An R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J Stat Softw"},{"issue":"6","key":"10.1016\/j.survophthal.2025.02.005_bib4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.01.021","article-title":"Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial","volume":"124","author":"Banerjee","year":"2017","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2025.02.005_bib5","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1097\/00006982-199212031-00015","article-title":"An overview of potential applications of heparin in vitreoretinal surgery","volume":"12","author":"Blumenkranz","year":"1992","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.survophthal.2025.02.005_bib6","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2025.02.005_bib7","article-title":"Isotretinoin and neuropsychiatric side effects: Continued vigilance is needed","volume":"6","author":"Bremner","year":"2021","journal-title":"J Affect Disord Rep"},{"issue":"1","key":"10.1016\/j.survophthal.2025.02.005_bib8","first-page":"65","article-title":"Retinoic acid promotes density-dependent growth arrest in human retinal pigment epithelial cells","volume":"32","author":"Campochiaro","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2025.02.005_bib9","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/1536867X1501500402","article-title":"Visualizing assumptions and results in network meta-analysis: The network graphs package","volume":"15","author":"Chaimani","year":"2015","journal-title":"Stata J"},{"issue":"3","key":"10.1016\/j.survophthal.2025.02.005_bib10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ajo.2008.05.002","article-title":"Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy","volume":"146","author":"Chang","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2025.02.005_bib11","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.ophtha.2004.05.036","article-title":"A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy","volume":"111","author":"Charteris","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2025.02.005_bib12","article-title":"Combined 5-fluorouracil and low molecular weight heparin for the prevention of postoperative proliferative vitreoretinopathy in patients with retinal detachment: a meta-analysis","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"22","key":"10.1016\/j.survophthal.2025.02.005_bib13","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1056\/NEJMcp0804591","article-title":"Clinical practice. Primary retinal detachment","volume":"359","author":"D'Amico","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.survophthal.2025.02.005_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/112067211002000224","article-title":"Effect of oral prednisolone on visual outcomes and complications after scleral buckling","volume":"20","author":"Dehghan","year":"2010","journal-title":"Eur J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2025.02.005_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11864-020-00771-7","article-title":"Optimal management of corticosteroids in patients with intracranial malignancies","volume":"21","author":"Dixit","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.02.005_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0420.1995.tb00043.x","article-title":"Ocular side effects associated with 13-cis-retinoic acid therapy for acne vulgaris: clinical features, alterations of tearfilm and conjunctival flora","volume":"73","author":"Egger","year":"1995","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.survophthal.2025.02.005_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3648134","article-title":"Anatomical and functional outcomes of vitrectomy with\/without intravitreal methotrexate infusion for management of proliferative vitreoretinopathy secondary to rhegmatogenous retinal detachment","volume":"2021","author":"El Baha","year":"2021","journal-title":"J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.02.005_bib18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/09273948.2019.1597894","article-title":"Intra-silicone oil injection of methotrexate in retinal reattachment surgery for proliferative vitreoretinopathy","volume":"28","author":"Falavarjani","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.survophthal.2025.02.005_bib19","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0161-6420(95)31007-X","article-title":"The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy","volume":"102","author":"Fekrat","year":"1995","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.survophthal.2025.02.005_bib20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.survophthal.2025.02.005_bib21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.sjopt.2014.03.005","article-title":"Effect of intraoperative 5-fluorouracil and low molecular weight heparin on the outcome of high-risk proliferative vitreoretinopathy","volume":"28","author":"Ganekal","year":"2014","journal-title":"Saudi J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.02.005_bib22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3928\/15428877-20070701-02","article-title":"Combined 5-fluorouracil, low-molecular-weight heparin, and silicone oil in the management of complicated retinal detachment with proliferative vitreoretinopathy grade C","volume":"38","author":"Garcia","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"8","key":"10.1016\/j.survophthal.2025.02.005_bib23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/BF00184858","article-title":"Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?","volume":"234","author":"Geoff Williams","year":"1996","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.02.005_bib24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/eye.2014.21","article-title":"Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy","volume":"28","author":"Ghasemi Falavarjani","year":"2014","journal-title":"Eye"},{"issue":"1","key":"10.1016\/j.survophthal.2025.02.005_bib25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2133.1997.17771864.x","article-title":"Treatment of acne with intermittent isotretinoin","volume":"137","author":"Goulden","year":"1997","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.survophthal.2025.02.005_bib26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrclinonc.2009.110","article-title":"Targeting angiogenesis: progress with anti-VEGF treatment with large molecules","volume":"6","author":"Grothey","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.survophthal.2025.02.005_bib27","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"12","key":"10.1016\/j.survophthal.2025.02.005_bib28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJM199009203231205","article-title":"Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck","volume":"323","author":"Hong","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2025.02.005_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2015.09.029","article-title":"Effect of serial intrasilicone oil bevacizumab injections in eyes with recurrent proliferative vitreoretinopathy retinal detachment","volume":"161","author":"Hsu","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.02.005_bib30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/IIO.0000000000000258","article-title":"Proliferative vitreoretinopathy: a review","volume":"59","author":"Idrees","year":"2019","journal-title":"Int Ophthalmol Clin"},{"issue":"3","key":"10.1016\/j.survophthal.2025.02.005_bib31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archopht.1991.01080030107048","article-title":"MS. Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy","volume":"109","author":"Katsura","year":"1991","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.02.005_bib32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.sjopt.2018.10.008","article-title":"5-Fluorouracyl added infusion fluid in patients with recurrent rhegmatogeneous retinal detachment","volume":"33","author":"Karakaya","year":"2019","journal-title":"Saudi J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.02.005_bib33","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.2500\/ajra.2011.25.3612","article-title":"The effectiveness of steroids for edema, ecchymosis, and intraoperative bleeding in rhinoplasty","volume":"25","author":"Koc","year":"2011","journal-title":"Am J Rhinol Allergy"},{"issue":"7","key":"10.1016\/j.survophthal.2025.02.005_bib34","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00417-011-1919-y","article-title":"Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial","volume":"250","author":"Koerner","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.02.005_bib35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1442-9071.2002.00554.x","article-title":"Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery","volume":"30","author":"Kumar","year":"2002","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.02.005_bib36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/0301-4738.21627","article-title":"Intravitreal low molecular weight heparin in PVR surgery","volume":"51","author":"Kumar","year":"2003","journal-title":"Indian J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2025.02.005_bib37","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/bjophthalmol-2018-312839","article-title":"Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial","volume":"103","author":"London","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2025.02.005_bib38","first-page":"3338","article-title":"Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy","volume":"43","author":"Mandava","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2025.02.005_bib39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1040-8428(85)80040-8","article-title":"13-Cis-retinoic acid: pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer","volume":"3","author":"Meyskens","year":"1985","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.02.005_bib40","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/bjo.2009.157727","article-title":"The epidemiology of rhegmatogenous retinal detachment: geographical variation and clinical associations","volume":"94","author":"Mitry","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2025.02.005_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.survophthal.2025.02.005_bib42","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4103\/ijabmr.IJABMR_469_16","article-title":"S. Retinoic acid embryopathy","volume":"7","author":"Mondal","year":"2017","journal-title":"Int J Appl Basic Med Res"},{"issue":"10","key":"10.1016\/j.survophthal.2025.02.005_bib43","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"1","key":"10.1016\/j.survophthal.2025.02.005_bib44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1350-9462(97)00007-4","article-title":"Risk factors for proliferative vitreoretinopathy","volume":"17","author":"Nagasaki","year":"1998","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.survophthal.2025.02.005_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4860743","article-title":"Real-life management of diabetic macular edema with dexamethasone intravitreal implant: A retrospective analysis of long-term clinical outcomes","volume":"2020","author":"Nicolo","year":"2020","journal-title":"J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.02.005_bib46","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41598-020-80005-w","article-title":"Molecular pathogenesis of rhegmatogenous retinal detachment","volume":"11","author":"\u00d6hman","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.survophthal.2025.02.005_bib47","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.survophthal.2025.02.005_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0039-6257(98)00023-X","article-title":"Proliferative vitreoretinopathy: an overview","volume":"43","author":"Pastor","year":"1998","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.02.005_bib49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1350-9462(01)00023-4","article-title":"Proliferative vitreoretinopathy: risk factors and pathobiology","volume":"21","author":"Pastor","year":"2002","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.survophthal.2025.02.005_bib50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.preteyeres.2015.07.005","article-title":"Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences","volume":"51","author":"Pastor","year":"2016","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"10.1016\/j.survophthal.2025.02.005_bib51","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3109\/02713681003597248","article-title":"Vitreous levels of VEGF, IL-8, and TNF-alpha in retinal detachment","volume":"35","author":"Rasier","year":"2010","journal-title":"Curr Eye Res"},{"issue":"4","key":"10.1016\/j.survophthal.2025.02.005_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019141","article-title":"Interleukin and growth factor levels in subretinal fluid in rhegmatogenous retinal detachment: a case-control study","volume":"6","author":"Ricker","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.survophthal.2025.02.005_bib53","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1007\/s00417-021-05206-z","article-title":"Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy","volume":"259","author":"Roca","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.02.005_bib54","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/02713688108998357","article-title":"Further characterization of epiretinal membranes in human massive periretinal proliferation","volume":"1","author":"Rodrigues","year":"1981","journal-title":"Curr Eye Res"},{"issue":"2","key":"10.1016\/j.survophthal.2025.02.005_bib55","article-title":"Netmeta: network meta-analysis using frequentist methods","volume":"1","author":"R\u00fccker","year":"2019","journal-title":"R Package Version"},{"key":"10.1016\/j.survophthal.2025.02.005_bib56","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.survophthal.2025.02.005_bib57","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2147\/OPTH.S111893","article-title":"Intravitreal methotrexate infusion for proliferative vitreoretinopathy","volume":"10","author":"Sadaka","year":"2016","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2025.02.005_bib58","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archopht.125.9.1161","article-title":"Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy","volume":"125","author":"Schiff","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.02.005_bib59","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1159\/000073067","article-title":"Primary vitrectomy in complicated rhegmatogenous retinal detachment--a survey of 205 eyes","volume":"217","author":"Schmidt","year":"2003","journal-title":"Ophthalmologica"},{"issue":"12","key":"10.1016\/j.survophthal.2025.02.005_bib60","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.ophtha.2010.03.033","article-title":"Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application","volume":"117","author":"Shen","year":"2010","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.survophthal.2025.02.005_bib61","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1159\/000066189","article-title":"Corticosteroids in ophthalmology: past\u2013present\u2013future","volume":"216","author":"Sherif","year":"2002","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.survophthal.2025.02.005_bib62","first-page":"1393","article-title":"Steroids as an adjunct for reducing the incidence of proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery: a systematic review and meta-analysis","volume":"9","author":"Shi","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.survophthal.2025.02.005_bib63","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2017047","article-title":"Network meta-analysis: application and practice using Stata","volume":"39","author":"Shim","year":"2017","journal-title":"Epidemiol Health"},{"issue":"2","key":"10.1016\/j.survophthal.2025.02.005_bib64","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00545968","article-title":"Reduction of pain and swelling by a corticosteroid injected 3\u2009h after surgery","volume":"23","author":"Skjelbred","year":"1982","journal-title":"Eur J Clin Pharm"},{"key":"10.1016\/j.survophthal.2025.02.005_bib65","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.survophthal.2025.02.005_bib66","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.survophthal.2025.02.005_bib67","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4103\/2008-322X.188390","article-title":"Intravitreal injection of bevacizumab in primary vitrectomy to decrease the rate of retinal redetachment: a randomized pilot study","volume":"11","author":"Tousi","year":"2016","journal-title":"J Ophthalmic Vis Res"},{"issue":"10","key":"10.1016\/j.survophthal.2025.02.005_bib68","first-page":"2830","article-title":"Effects of vitamin A on retinal pigment epithelial cells in vitro","volume":"33","author":"Verstraeten","year":"1992","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2025.02.005_bib69","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ophtha.2006.08.042","article-title":"Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy","volume":"114","author":"Wickham","year":"2007","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2025.02.005_bib70","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0002-9394(98)00115-9","article-title":"Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial","volume":"126","author":"Wiedemann","year":"1998","journal-title":"Daunomycin Study Group Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.02.005_bib71","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1159\/000529451","article-title":"Steroid drugs as an adjunct for reducing the incidence of proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery: a meta-analysis of randomized controlled studies","volume":"66","author":"Xu","year":"2023","journal-title":"Ophthalmic Res"},{"issue":"9","key":"10.1016\/j.survophthal.2025.02.005_bib72","first-page":"5221","article-title":"Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade","volume":"53","author":"Xu","year":"2012","journal-title":"J Ophthalmic Vis Res"},{"issue":"3","key":"10.1016\/j.survophthal.2025.02.005_bib73","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/IAE.0000000000001584","article-title":"Efficacy of intravitreal injection of bevacizumab in vitrectomy for patients with proliferative vitreoretinopathy retinal detachment: a meta-analysis of prospective studies","volume":"38","author":"Zhao","year":"2018","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.survophthal.2025.02.005_bib74","first-page":"443","article-title":"A different look at corticosteroids","volume":"58","author":"Zoorob","year":"1998","journal-title":"Am Fam Physician"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725000335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725000335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T13:30:12Z","timestamp":1747488612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625725000335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0039625725000335"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.02.005","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological agents for treatment of proliferative vitreoretinopathy: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}